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Abstract 
Rabies is nearly 100% fatal without the pre-or post-exposure prophylaxis 
vaccination series.  Pre-exposure Prophylaxis (PrEP) vaccination series is administered to 
those persons in high risk occupations due to the evidence that PrEP is the most effective 
method of protection from a rabies infection.  Rabies virus neutralizing antibody (RVNA) 
is required for the protection from rabies.  However, the immune mechanism and 
antibody kinetics of isotype switching remains unclear by current diagnostic techniques.  
Knowledge of these kinetics will aid in making more informed decisions on the timing 
and number of vaccinations needed to elicit a sufficient antibody response for protection 
against exposure to rabies virus.  Recently, the World Health Organization (WHO) 
supported alternative vaccine regimens that may affect peak levels of these subclasses of 
RVNA.  Advisory Committee on Immunization Practices (ACIP) is also currently 
evaluating the rationale for ideal vaccine series for amending the current rabies 
prevention recommendations.  To date, there has not been a rapid and reliable assay to 
detect and quantify antibody isotype switching from the primary antibody response of 
IgM to the subsequent IgG antibody response that occurs during the immune response to 
rabies vaccination.  The principal requirement of this assay is that it can reliably and 
reproducibly determine and correlate responses to RVNA levels and monitor IgG versus 
IgM response, according to current guidelines.  This knowledge will aid in the 
understanding of the immune response as a result of rabies virus infection or 
immunization using a currently approved vaccine and provide additional information to 
guide future research. 
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Chapter 1 - Introduction to Rabies Virus, Immune Response, 
and Current Diagnostics 
 1.1 Rabies Background 
Rabies is considered one of the most lethal infectious diseases, with a case fatality 
rate of nearly 100% (without the receipt of pre-exposure prophylaxis consisting of the 
recommended vaccination series), well above other high profile infectious diseases such 
as Ebola (59-90%) and HIV/AIDS (80-90%) [1–4].  It remains prevalent in several 
regions of the world, and is endemic on all continents with a heavy burden in Africa and 
Asia [1,5].  Varying risk levels viewed in Figure 1. Distribution of Risk Levels for 
Humans contacting Rabies (2013) show moderate risk (indicated by dark green) through 
no risk (indicated by white) for all regions.   
 
Figure 1. Distribution of Risk Levels for Humans Contacting Rabies (2013) [6] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Distribution of the varying risk levels for humans contacting rabies throughout the world as compiled 
by the World Health Organization from 2013. 
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Rabies is nearly 100% preventable if post exposure prophylaxis, consisting of 
wound cleansing (most important), administration of rabies immune globulin (RIG), and 
a series of four rabies vaccinations administered on days 0, 3, 7 and 14 as per the 
recommendation of the Advisory Committee on Immunization Practices, is received 
without delay [7,8].  Individuals previously vaccinated against rabies only receive the 
post-exposure vaccination series as a booster and not RIG [9].  Also, see Figure 2. World 
Health Organization (WHO) Position: Recommended Schedules for more detailed post-
exposure prophylaxis guidelines [5].  When administering the vaccination series effective 
immunization can be achieved with reduced doses, and hence reduced cost, with a 
modification of the current vaccination schedule [5,10]. The World Health Organization 
has approved the use of a two dose vaccination series administered on day 0 and again on 
day 7 [5]. 
 
Figure 2. World Health Organization (WHO) Position: Recommended Schedules [5] 
 
Recommended post-exposure prophylaxis (PEP) by the World Health Organization updated in 2018 
for the varying categories of exposure for both naïve and previously vaccinated individuals. 
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 Rabies virus (RABV) is an unsegmented, single-stranded, negative-sense, 
enveloped RNA virus.  It belongs in the order Mononegavirales, is in the Rhabdoviridae  
family, and belongs to the Lyssavirus genus of which there are fourteen species and three 
phylogroups [5,11].  RABV falls into the phylogroup I category and consists of five 
proteins that provide structural and functional support [11,12].  Viral replication and 
translation occur in the ribonucleoprotein complex that consists of the nucleoprotein (N), 
RNA-dependent RNA polymerase (L), and phosphoprotein (P) [1,13–15].  Neutralization 
of viral protein epitopes which bind host-cell receptors is crucial for protection against 
RABV via administration of rabies vaccines and immunoglobulin (RIG). This 
neutralization relies upon the tertiary structure formation of the matrix (M) and most 
importantly the glycoprotein (G).  G alone is also effective for anti-rabies antibody 
production where monoclonal antibodies are used [12,16,17].   
Clinical presentation begins similarly to most viral infections with the onset of 
flu-like symptoms to include, but not limited to fever, headache, anxiety, sore throat and 
cough [18,19].  Upon exposure, the virus travels through the outer tissues to the motor 
neurons where it spreads from cell to cell via the synaptic junctions and finally to the 
spinal cord and brain [19].  Clinically the disease manifests as either the paralytic or 
“furious” form that is caused by infection of the central nervous system [20–22].  More 
commonly, the furious form presents in approximately 80% of human cases with the 
typical signs of aggression; the less common paralytic form occurs in approximately 20% 
of cases and symptoms are lethargy and eventually paralysis that often goes 
misdiagnosed [19].  Ultimately it is acute encephalitis that leads to symptoms, coma, and 
death for either form of the disease [21,23].   
 
 1.2 Vaccines and the Immune Response 
 This section describes the immunological response and the cell types and other 
components involved in antibody production.  The immunological response is important 
to understand the rationale for designing a separate IgM and IgG assay.  
Concentrated cell culture and embryonated egg-based rabies vaccines (CCEEVs) 
are currently administered both via the intradermal (ID) and intramuscular (IM) routes 
[5,13].  ID injections allow a lower dosage than IM due to the aid of antigen-presenting 
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dendritic cells (APCs) that are abundantly present in the dermis [12,24].  APCs then act 
as a vehicle to rapidly process these antigens into peptides and present these antigen 
peptides via MHC II to CD4+ T-cells for activation of cytokine production that lead to 
class switching and elicit a strong immune response by antigen specific B-cells in a 
typical T cell-dependent B-cell response [24–26].  Antigen is bound to the Fab region on 
the B-cell receptor with secondary signaling from cytokines released by the previous 
CD4+ T-helper cells [27].  Somatic hypermutation occurs at the Fab region for better 
antigen fit and B-cells mature into plasma cells secreting IgM antibody followed by 
generation of memory B-cells [27].  Clones of these best antigen fit B-cells are produced 
that then go on to form more plasma cells and T-cell cytokines signal class switching for 
production of strongly neutralizing, long lasting IgG antibodies, see Figure 3 [25–27].  
Upon repeat exposure (secondary immune response) to the antigen and clonal expansion 
of B-cells in lymphoid tissue, the response time is decreased and amount of neutralizing 
antibodies are increased via the process of affinity maturation during the humoral 
immune process [28]. 
 
Figure 3. Immune Response to Rabies Vaccination 
 
The T-cell dependent B-cell immune response to rabies vaccination, including clonal expansion and 
class switching to highly neutralizing IgG antibody production. 
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IgM is the first immunoglobulin to respond in the presence of viral antibodies 
(IgM is primarily developed in plasma cells as a result of B cell activation) and IgG 
develops via T cell dependent immune response for lasting (humoral) immunity against 
an invading pathogen [25,26].  A rapid response is required by the primary immune 
system to be effective in recognizing and defending against pathogens, specifically rabies 
virus in this case [29,30].  As a result of this necessary function, the structure follows suit 
with IgM being a pentameric molecule capable of grabbing hold of up to ten epitopes of 
antigens [31]. 
IgG develops as a monomeric molecule against a specific antigen exposure as a 
result of the initial IgM primary response via class switching [28].  Affinity maturation is 
a result of selection of high affinity clones for expansion within the lymph nodes [28].  
These responses trigger lasting immunity and a memory response via B-cells producing 
the immunoglobulin rapidly upon repeat exposure to the same antigen [32].  These 
antibodies are created in a specific manner dependent upon the type of antigen and are 
divided into four subclasses of IgG (IgG1 through IgG4) [33].  IgG antibody is the most 
prevalent in serum and has the ability to diffuse into tissues, unlike IgM which is short 
lived and cannot cross into tissues. [24–26,32,34]. 
 
 1.3 Current Diagnostics 
The following sections describe diagnostic detection of anti-rabies antibodies in 
patient sera. 
 1.3.1 RFFIT  
Rapid Fluorescent Focus Inhibition Test is an antibody mediated virus 
neutralization test and is the most widely accepted assay for the quantitation of functional 
antibodies against rabies virus. The assay is performed in two stages (1) a virus-
neutralization step, in which a standard dose of virus is mixed with the serial dilutions of 
a serum sample, and (2) an inoculation step, in which tissue culture cells are added to the 
reaction mixture. The absence or reduction of infectivity constitutes a positive 
neutralization reaction and indicates the presence of virus-specific antibodies in the test 
serum sample. The sensitivity of this neutralization test system (for measuring the growth 
of residual non-neutralized viruses) and the virus replication cycle time defined by the 
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virus challenge dose to be used in the test assay. The precision with which the amounts of 
residual infectious virus can be measured is based on the sensitivity and specificity of the 
assay readout system. A fluorochrome conjugated anti-N protein rabies-specific antibody 
is used to measure the residual rabies virus infectivity [29,35,36].  This conjugate 
measures functional neutralization against the virus, not necessarily against specific Ig 
classes (can detect both IgM and IgG concurrently) [36,37]. 
 
 1.3.2 ELISA 
 Indirect enzyme-linked immunosorbent assays (ELISA) are relatively inexpensive 
with a fast turnaround time compared to other serological testing methods.  The assay 
uses adherence of antigens to the bottom of a micro well plate in combination with the 
following five principles: (1) an antigen-antibody immune reaction, (2) addition of 
secondary anti-rabies antibody coupled to a detector recognized by the substrate, (3) 
chromogenic product formed from a colorless substrate via an enzymatic chemical 
reaction, (4) stop solution added to cease the enzymatic reaction, (5) signal detection via 
a microplate reader and quantification of the optical density (OD) generated in the 
enzymatic reaction, see Figure 4. These in combination make this assay type one of the 
most specific and sensitive immunoassays to detect the biological molecule/protein of 
interest.  By comparing the OD of the sample to the reference standard curve, the relative 
potency of the sample can be determined and expressed in equivalent units (EU/mL) 
[29,35,38,39].  Alternative secondary antibody (conjugates) can be varied for a wider 
range of detection utilizing the same basic assay components.  EU/mL is a unit equivalent 
to the international units defined by seroneutralization (RFFIT). 
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Figure 4. Anti-Rabies Indirect ELISA Procedure 
 
 Used in this assay development is the Platelia Rabies II kit which is an indirect 
immune-enzymatic technique allowing the detection of IgG antibodies directed against 
rabies virus glycoprotein (“Bio-Rad Platelia TM Rabies II Kit for in vitro Detection and 
Titration of IgG anti-Rabies Virus Glycoprotein in Human Serum and Plasma. Ref.:355-
1180” 2015).  Serum samples are distributed on a solid phase sensitized with purified 
rabies virus glycoprotein.  The complex rabies antibodies/glycoprotein is revealed by the 
addition of an enzymatic conjugate (protein A derived from Staphylococcus aureus 
labeled with peroxidase allows for multi-species evaluation and binds preferentially to 
the Fc portion of IgG) [41–43].  The quantity of rabies antibodies in the sample is 
determined by comparing the OD of the sample to the R4b standard curve drawn from 
the quantification standards (S1 to S6) calibrated against the international WHO standard 
and proven to display equivalent binding compared to IgG.  Validation results of the Bio-
Rad Platelia Rabies Kit II against reference techniques (RFFIT) are published [43,44]. 
 
Indirect ELISA procedure utilizing rabies glycoprotein antigen coated micro titer wells to measure IgG 
or IgM in patient sera in response to rabies vaccination coupled with anti-IgG, anti-IgM, and Protein A 
horseradish peroxidase (HRP) labeled conjugate in combination with tetramethylbenzidine (TMB) 
substrate diluted into peroxydase substrate solution used as the detector. 
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 1.4 Rationale for New Diagnostics 
Gold standard diagnostic tests are currently validated, accepted, and in use. 
However, more recently, alternative vaccine regimens have been supported by WHO that 
may affect the timing of seroconversion or quantity of the different classes of rabies virus 
neutralizing antibodies (RVNA) [5].  That difference in timing will have an effect across 
the board on all processes related to rabies PrEP and Post Exposure Prophylaxis (PEP).  
Use of measurement of rabies antibodies in human serum or donor plasma can be used to 
evaluate response to PrEP/PEP or to manage the production process of rabies immune 
globulin used in PEP in naïve individuals. This evaluation will push forward the ability to 
monitor and quantify rabies vaccine efficacy by monitoring isotype switching during 
vaccination, the specific timing of that switch, the contribution of each to RVNA, the 
result of affinity maturation to greater specificity and neutralizing function and better 
select plasma donors for manufacturing of rabies PEP immunoglobulin.  The 
establishment and validation of this ELISA assay would be the first of its kind in 
distinguishing between anti-rabies IgG versus IgM and would add increased quantitation 
of the rabies immune response over the RFFIT and ELISA methods currently validated 
and utilized. 
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Chapter 2 - Proof of Concept and Study Design 
The following sections describe previously performed proof of concept testing in 
the formulation of this assay development and the overall objectives in the development 
and evaluation of the IgM and IgG assays. 
 
 2.1 Proof of Concept 
Anti-human IgG and IgM conjugate dilutions as well as a control sera for 
establishing an IgM standard curve for proof of concept testing were previously assessed 
by Amy Lyons and Dr. Susan Moore.  A conjugate dilution of 1:10,000 for IgM and 
1:6,400 for IgG were found to be optimal and were used as the starting reference point in 
this evaluation.  A day 7 post vaccination serum sample was chosen to be the curve 
standard for establishment of the IgM quantitative assay and the kit supplied R4b 
standard was assessed against the IgG conjugate for establishment of the IgG quantitative 
assay. 
 
 2.2 Objective 
The objective of the proof of concept study and the subsequent assay evaluation 
was to reliably detect and quantify the rabies specific IgG and IgM antibody response to 
vaccination and relate those antibodies to the rabies virus-neutralizing antibody (RVNA) 
response of the individuals who received the rabies vaccination series.  Comprehensive 
investigation of the immune reaction of each individual's response to vaccination may 
contribute to our understanding of the variability of immunoglobulin class switching 
between individuals, potentially predict high versus low responder’s effective immune 
defense in correlation between titer value and Ig class, and help guide future research of 
preventative and treatments options. 
 
 2.3 Proposed Method 
Evaluation of this rabies ELISA technique targeting IgG and IgM in human 
sera will be assessed based upon a currently validated assay for detection of IgG in 
animal and human serum/plasma.  This method is currently utilized for anti-rabies 
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glycoprotein detection in animal samples for monitoring of oral rabies vaccine baiting 
programs and in human plasma donors for rabies immunoglobulin production 
programs.  This evaluation will push forward the ability to monitor and quantify rabies 
vaccine efficacy by monitoring isotype switching during vaccination, and better select 
plasma donors for the manufacturing of rabies post-exposure prophylaxis (PEP) 
immunoglobulin.  IgM is the first immunoglobulin to respond in the presence of a viral 
infection and is primarily developed in plasma cells, IgG develops second. Long-lived 
plasma cells and memory cells combine for lasting (humoral) immunity against an 
invading pathogen.  The establishment and validation of this assay would be the first of 
its kind in distinguishing between anti-rabies IgG versus IgM and would add increased 
quantitation of the rabies immune response over the immunofluorescent assay (IFA) 
method currently validated and utilized.  This would provide clients with a more rapid 
option for evaluation of the sera samples sent in for routine rabies titer checks. 
 
 2.4 Participants 
Unvaccinated Kansas State Veterinary Diagnostic Laboratory (KSVDL) 
employees that have given consent to have multiple blood draws for a representative 
sampling from Day 0 to Day 35 post vaccination with an FDA approved rabies vaccine 
were used in the collection of serum from each whole blood sample.  This will ensure 
that there is adequate sera volume for both IgM and IgG quantitation and assay 
evaluation. Samples were de-identified as per the protocol reviewed and approved by 
IRB#1132. 
 2.5 Design 
Platelia Rabies II ELISA kit (Ref: 355-1180) manufactured by Bio-Rad, which 
is currently validated for use to detect rabies virus glycoprotein in serum and plasma 
from humans was modified to evaluate human sera at varying blood draw days from 0 
to 35 days post vaccination to detect IgG and IgM.  Anti-human IgG (Sigma Cat# 
A0170) and anti-human IgM (Sigma Cat# A6907) HRP conjugates will be utilized and 
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evaluated in place of the kit supplied Protein A HRP conjugate. KSVDL Rabies 
antibody internal standards will be utilized as standards for comparison. 
 
Table 1. Protein A ELISA Standard Curve Generation and Concentration 
 
 
Table 2. Example Microplate Layout with Quantitative Method 
 
 
Quantification 
standards
S6
S1
S2
S3
S4
S5
Concentrations obtained by serial 
dilutions of the R4b Positive control
0.125 EU/mL
0.25 EU/mL
0.5 EU/mL
1 EU/mL
2 EU/mL
4 EU/mL
S2 diluted to 1:2
S3 diluted to 1:2
S4 diluted to 1:2
S5 diluted to 1:2
S6 diluted to 1:2
R4b diluted to 1:100
1 2 3 4 5
A R3 S4 Sample 1 Sample 9 …
B R3 S4 Sample 2 Sample 10
C R4a S3 Sample 3 Sample 11
D R4a S3 Sample 4 Sample 12
E S6 S2 Sample 5 Sample 13
F S6 S2 Sample 6 Sample 14
G S5 S1 Sample 7 Sample 15
H S5 S1 Sample 8 Sample 16
R4b 4 EU/mL positive control supplied by BioRad Platelia II Rabies ELISA kit.  Manufacturers 
recommended dilution scheme and theoretical concentrations for each point on the standard curve 
utilized in the quantitative calculation of anti-rabies IgG in patient sera. 
Recommended plate set-up as per the Bio-Rad Platelia II Rabies ELISA kit manual including the kit 
supplied standards: R3 (negative control), R4a (0.5 EU/mL positive control), R4b (4 EU/mL positive 
control), and patient sera.  R3, R4a, and patient samples are all diluted to the recommended 1:100 
dilution prior to addition to the micro titer plate. 
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 2.6 Procedure 
 A suitable IgM control sera will be utilized for establishing a standard curve 
similar to the R4b standard against Protein A conjugate (range of 0.125 to 4 EU/mL) 
used in the kit.  Previously, the kit supplied R4b was used in establishment of the IgG 
standard curve.  This development and evaluation will reassess that standard as the 
best fit for the IgG curve and delve into alternative samples for the establishment of a 
suitable IgG standard curve sample that provides a similar curve fit as compared to the 
kit supplied standard and conjugate.  Further experimentation will be required to 
optimize and standardize the conjugate dilutions for each analyte.  Incubation times 
and suggested dilutions will follow the manufacturer’s kit instructions during 
establishment of appropriate conjugate dilutions and IgM and IgG standard curve 
creation.  Based upon the proof of concept testing, those sample values (OD and 
EU/mL) alongside the average days post vaccination (DPV) will be the starting point 
for determining the optimum conjugate dilution for IgG and IgM.  Followed by testing 
the reproducibility of the standard curve for IgM utilizing sample RAE-2 with a pre-
dilution of 1:100 followed by serial two-fold dilutions for the positive control sera 
comparison. 
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Chapter 3 - Materials and Methods 
The next sections describe the methodology behind all testing including RFFIT, 
Protein A, anti-IgM, and anti-IgG conjugated indirect ELISAs including standard curve 
development for the IgM and IgG assays. 
 
 3.1 RFFIT Materials & Methods 
 3.1.1 Challenge Virus   
CVS-11 (challenge virus standard – 11) strain of rabies virus was evaluated as the 
challenge virus in the RFFIT assay used to quantitate the amount of RVNA present in 
serum samples. The CVS-11 strain was obtained from the Centers for Disease Control 
and Prevention (ATCC).  Seed virus of the CVS-11 was grown on BHK cells to produce 
stock virus. Stock virus preparations were titered to obtain a working dilution of 50 
TCID50. 
  
 3.1.2 Serum samples   
Serum samples used in the analysis were obtained from ten subjects who had 
received the same pre-exposure vaccination regimen with vaccine administered on days 
0, 7, 21 or 28 as per the current ACIP guidelines.  Serum samples that were collected on 
days 0, 7, 14, 21, 28, and 35 after initial vaccination were included in the study, in some 
instances a day 42 post vaccination sample was also obtained.  Samples were coded using 
RAE- , to represent “Rabies Antibody ELISA” as is the intended purpose for the 
collection and storage of this sample set.  All samples were heat-inactivated for 30 
minutes at 56°C to remove complement factors that have been proven to interfere with 
neutralization. A pool of serum from unvaccinated subjects was used as the rabies 
antibody negative control. 
 
 3.1.3 Serological testing  
RFFIT, using CVS-11 as the challenge virus strain was used to assay all serum 
samples for the baseline rabies virus neutralizing antibody (RVNA) titer value, as 
previously described (Smith, 1996).  Testing was performed at the Kansas State 
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University Rabies Lab (Manhattan, KS).  First, 100 μL of each serum sample was diluted 
in serial five-fold dilutions in 96-well microplates utilizing robotics for the dilution step 
via BioTek precision automated diluters and 100 µL if each serum dilution loaded into 8-
well Lab-Tek chamber slides (Nunc™ Lab-Tek™ Chamber Slide System , catalog# 
177445) after which 100 μL of the challenge virus, at a concentration of 50 TCID50, was 
added (see Figure 5. RFFIT Endpoint 96-well Plate Dilutions and Figure 6 RFFIT 
Endpoint Transfer to 8-well Lab-Tek Slides).  Viral addition results in a two-fold dilution 
for end titer values of 1:5, 1:25, 1:125, and 1:625.  Exact endpoint titers for high-titer sera 
were obtained when initial titer results were above the upper limit of quantitation (> 15.0 
IU/mL).  High-titer sera was pre-diluted in RFFIT media to obtain a readable result 
within the linear range of the assay (0.1 IU/mL to 15.0 IU/mL) as defined in the current 
version KSU RFFIT Validation Report (2015). 
 
Figure 5. RFFIT Endpoint 96-well Plate Dilutions 
 
 
 
Dilution schematic for the Rapid Focus Fluorescent Inhibition Test (RFFIT).  Media addition to the 
96-well plate and dilutions performed via automated Bio-Tek precision automated diluters, initial 
samples are loaded manually by a trained technician.  Serum dilutions are 1:2.5, 1:12.5, 1:62.5, and 
1:312.5 after diluting. 
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Figure 6. RFFIT Endpoint Transfer to 8-Well Lab-Tek Slides 
 
Slides were incubated at 37oC ± 2 oC for 90 minutes ± 5 minutes after which 
200μL of a suspension containing 5 X 105 BHK cells (American Tissue Cell Culture-
ATCC, Catalog # CCL-10) were added to each well. Slides were placed in a 2-5% CO2 
incubator at 37oC ± 2 oC for 20-24 hours.  After incubation, the slides were washed and 
fixed in 80% cold acetone, dried and stained with FITC conjugated anti-rabies antibody 
(anti-N, Millipore Sigma Catalog #5500). Twenty fields per well were examined under 
100X magnification using a fluorescence microscope for the presence of rabies virus and 
RVNA titers were calculated using the Reed and Muench method (Habel, 1996).  
International units were calculated from the serum titer using the following formula: 
 
Equation 1. Reed and Muench RVNA Titration Calculation 
Endpoint titer of test serum  X 2.0 IU/mL reference serum 
Endpoint titer of reference serum 
 
 
 
 
 
Following serum dilutions in Figure 4. RFFIT Endpoint 96-well Plate Dilutions, 100 µL of each diluted 
serum is added to a separate well in an 8-well chamber slide as per the schematic below. 
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Table 3. RFFIT Endpoint Titer Results 
 
 
As expected, the day 0 samples display results below the limit of quantitation (</ 
0.1) and the titer result increases after each vaccination with a leveling off and 
stabilization of antibodies near the day 42 post vaccination draw date, see Table 3. 
 
 3.2 Protein A ELISA Materials and Methods 
After the baseline gold standard RFFIT titer values were established for each 
sample, the next step in this evaluation was to obtain the Protein A ELISA titer values. 
 3.2.1 Kit 
PlateliaTM Rabies II Kit (Marnes-la-Coquette, France) Ref: 355-1180 for in vitro 
detection and titration of IgG anti rabies virus glycoprotein in human serum and plasma 
Sample 
ID:
DPV: Results (IU/mL):
Sample 
ID:
DPV: Results (IU/mL):
Sample 
ID:
DPV: Results (IU/mL):
RAE-1 0 </= 0.1 RAE-18 42 24.4 RAE-35 0 0.1
RAE-2 14 17.5 RAE-19 0 </= 0.1 RAE-36 0 </= 0.1
RAE-3 21 23.9 RAE-20 7 0.5 RAE-37 16 10.0
RAE-4 28 106.8 RAE-21 14 9.9 RAE-38 31 32.4
RAE-5 42 84.7 RAE-22 21 11.3 RAE-39 0 </= 0.1
RAE-6 0 </= 0.1 RAE-23 28 26.1 RAE-40 16 </= 0.1
RAE-7 7 2.0 RAE-24 42 18.5 RAE-41 31 5.3
RAE-8 14 12.5 RAE-25 0 </= 0.1 RAE-42 0 </= 0.1
RAE-9 21 11.3 RAE-26 7 0.9 RAE-43 7 </= 0.1
RAE-10 28 28.6 RAE-27 21 25.0 RAE-44 21 5.3
RAE-11 42 27.3 RAE-28 28 13.5 RAE-45 42 14.3
RAE-12 0 </= 0.1 RAE-29 0 </= 0.1 RAE-55 0 </= 0.1
RAE-13 7 </= 0.1 RAE-30 7 </= 0.1 RAE-56 7 </= 0.1
RAE-14 10 0.2 RAE-31 14 0.6 RAE-57 14 13.1
RAE-15 14 3.2 RAE-32 21 1.2 RAE-58 28 7.7
RAE-16 21 11.9 RAE-33 28 1.2 HRIG HRIG 10.0
RAE-17 28 10.1 RAE-34 42 2.9
Rapid Focus Fluorescent Inhibition Test endpoint titer results measuring functional/neutralizing 
antibodies expressed in IU/mL (International Units) for all Rabies Antibody ELISA (RAE) samples 
using CVS-11 (Challenge Virus Standard) as the neutralizing virus to determine baseline titer values.  
Below limit of quantitation results display as “</= 0.1” and any samples with titers > 15.0 (the assay 
upper limit) were pre-diluted prior to following the dilution scheme in Figure. 5. Samples RAE-1 
through RAE-5, as indicated by the red box (also denoted by shading), correspond to a single patient 
for all draw dates (expressed in days post vaccination (DPV).  RAE-35 corresponds to pooled negative 
samples. 
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was used for baseline IgG titer value in (equivalent units) EU/mL. The kit contains wells 
coated with rabies glycoprotein (G-protein) for use as the antigen in an 8-well per strip 
format with a secondary horseradish peroxidase (HRP) enzyme conjugated 
Staphylococcus aureus protein A (preferentially detects the Fc portion of IgG) followed 
by a tetramethylbenzidine (TMB) substrate that produces a colormetric reaction.  Lastly, 
stop solution (1N sulphuric acid) is added to stop the enzymatic reaction.  Version 
881179 – 2015/06 kit instructions were followed to obtain the titer value in EU/mL which 
were calculated by comparison of the sample optical density reading against a standard 
curve of positive standards, calibrated to the WHO standards, supplied in the kit (R4b 
standard range: </= 0.125 to >/= 4 EU/mL). 
 
 3.2.2 Serum samples 
Same as assayed under section 3.1.2 RFFIT Materials & Methods, section Serum 
Samples. 
 
 3.2.3 Serological testing 
The indirect ELISA method, Bio-Rad Platelia Rabies Kit II ELISA (Marnes-la-
Coquette, France) was performed at the Kansas State University Rabies Lab (Manhattan, 
KS) per the manufacturer’s instructions.  Kit supplied controls, R3, R4a, and R4b were 
diluted 1:100 using 10 µL sample and 990 µL of R6 diluent; when diluted 1:100, R4b = 
S6 in the standard curve.  S6 was then serially diluted 1:2 using 500 µL of the previously 
made S6 and 500 µL R6 diluent to produce S5.  Serial dilutions were continued using the 
same pipettes and volumes to produce S4, S3, S2, and S1 (S5 was diluted 1:2 to produce 
S4; S4 was diluted 1:2 to produce S3; S3 was diluted 1:2 to produce S2; S2 was diluted 
1:2 to produce S1). Internal standards MMP-4, 0.5 Ref2017, and FBS were diluted 1:100 
using 10 µL of standard and 990 µL R6 diluent.   Samples RAE-4, -5, -10, -11, -16, -17, -
18, -23, -24, -27, 28, 38, -45, -57, and HRIG were pre-diluted 1:10 using 20 µL sample 
and 180 µL R6 diluent.  Pre-dilutions were initially determined on the basis of the RFFIT 
IU/mL results in correlation with the upper limit of the ELISA assay of 4.0 EU/mL.  All 
other samples were tested neat on the assay.  Internal standard Ref2017 was diluted 1:50 
using 30 µL of standard and 1470 µL of R6 diluent used as a dilution control. See Figure 
18 
7 for plate layout. Once all pre-dilutions were performed samples and internal standards 
were diluted 1:100 per the Bio-Rad kit instructions using 10 µL sample and 990 µL R6 
diluent. Once all 1:100 assay dilutions had been prepared, 100 µL of each sample (all 
controls, internal standards, and samples) were added to the micro titer plate, covered 
with adhesive film, and incubated at 37°C ± 2°C for 60 ±5 minutes.  The plate was 
removed from the incubator, adhesive film removed, and prepared wash solution (10X 
R2) was used to perform three wash cycles with 300 µL per well each cycle.  Conjugate 
solution (R7) was prepared at a 1:10 dilution using R2 as the diluent, 100 µL added to 
each well, new adhesive film added, and incubated at 37°C ± 2°C for 60 ±5 minutes.  The 
plate was removed from the incubator, adhesive film removed, and prepared wash 
solution (10X R2) was used to perform five wash cycles with 300 µL per well each cycle.  
TMB substrate solution (R9) was prepared at a 1:11 dilution using R8 as the diluent, 100 
µL added to each well away from direct light, and incubated uncovered at +18°C to 
+30°C for 30 ± 5 minutes in the dark.  Finally, 100 µL of Stop Solution (R10) was added 
to each well and read immediately on a microplate reader at 450 and 630 nm to obtain the 
OD readings and the delta OD determined. 
A Bio-Tek ELx808 microplate reader (Winooski, VT) coupled with Gen 5 
(version 2.06) software set to the manufacturer’s specifications for the quantitative kit 
parameters were used alongside the proprietary Bio-Rad Platelia II calculations in the 
Excel results workbook to obtain the results in EU/mL for each sample (see Figure 7. 
Bio-Rad Platelia II Result Excel Sheet).  Samples producing results above the kit upper 
level of quantitation (ULOQ) were further diluted and retested to obtain an endpoint 
result within the quantitative range of each assay. 
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Figure 7. Bio-Rad Platelia II Result Excel Sheet 
 
 
 
 
 
Indirect enzyme-linked immunosorbent assay (ELISA) Excel sheet for obtaining endpoint titer results 
expressed in EU/mL (Equivalent Units) for all samples using Protein A at a dilution of 1:10 as the 
secondary conjugate.  Optical density (OD) values are input (into the yellow fields) in the top sheet 
along with sample IDs (in grey fields).  Proprietary calculations assess criteria of the kit standards and 
generate a standard curve to obtain a quantitative titer result (EU/mL) for each sample. 
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Table 4. Protein A ELISA Results 
 
As expected, the day 0 samples display results below the limit of quantitation (</ 
0.125) and the EU/mL titer result increases after each vaccination with a leveling off and 
stabilization of antibodies near the day 42 post vaccination draw date, see Table 4.  The 
internal standards (Ref2017, MMP-4, 0.5Ref2017, and FBS) all correspond to the 
expected values and provide the interassay validity between the initial assay and 
subsequent assays runs to include the pre-dilutions for endpoint titration.  In addition, the 
kit supplied standards (R3, R4a, and R4b) produce appropriate values against the 
expected. 
 
Sample 
ID:
DPV:
Results 
(EU/mL):
ELISA 
ID:
DPV:
Results 
(EU/mL):
Sample 
ID:
DPV:
Results 
(EU/mL):
RAE-1 0 </= 0.125 RAE-21 14 1.40 RAE-41 31 3.72
RAE-2 14 3.30 RAE-22 21 2.95 RAE-42 0 </= 0.125
RAE-3 21 3.86 RAE-23 28 16.62 RAE-43 7 </= 0.125
RAE-4 28 13.84 RAE-24 42 12.38 RAE-44 21 1.94
RAE-5 42 13.02 RAE-25 0 </= 0.125 RAE-45 42 9.62
RAE-6 0 </= 0.125 RAE-26 7 </= 0.125 RAE-55 0 </= 0.125
RAE-7 7 </= 0.125 RAE-27 21 7.73 RAE-56 7 </= 1.25
RAE-8 14 1.05 RAE-28 28 6.42 RAE-57 14 6.92
RAE-9 21 1.56 RAE-29 0 </= 0.125 RAE-58 28 2.19
RAE-10 28 18.25 RAE-30 7 </= 0.125 HRIG HRIG 14.44
RAE-11 42 18.07 RAE-31 14 0.24 Ref2017 Ref2017 24.81
RAE-12 0 </= 0.125 RAE-32 21 0.46 MMP-4 MMP-4 0.14
RAE-13 7 </= 0.125 RAE-33 28 0.55 0.5Ref2017 0.5Ref2017 0.39
RAE-14 10 </= 0.125 RAE-34 42 3.92 FBS FBS </= 0.125
RAE-15 14 0.75 RAE-35 0 0.20 R3 R3 </= 0.125
RAE-16 21 8.97 RAE-36 0 </= 0.125 R3 R3 </= 0.125
RAE-17 28 7.47 RAE-37 16 1.46 R4a R4a 0.46
RAE-18 42 27.57 RAE-38 31 9.23 R4a R4a 0.45
RAE-19 0 </= 0.125 RAE-39 0 </= 0.125 R4b R4b 4.09
RAE-20 7 </= 0.125 RAE-40 16 </= 0.125 R4b R4b 3.93
Indirect enzyme-linked immunosorbent assay (ELISA) endpoint titer results expressed in EU/mL 
(Equivalent Units) for all samples using Protein A at a dilution of 1:10 as the secondary conjugate.  
Below limit of quantitation results display as “</= 0.125” and any samples with titers > 4.0 (the assay 
upper limit) were pre-diluted prior to following the manufacturer 1:100 assay dilution.  Samples RAE-1 
through RAE-5, as indicated by the red box (also denoted by shading), correspond to a single patient 
for all draw dates (expressed in days post vaccination (DPV).  RAE-35 corresponds to pooled negative 
samples.  Internal standards are indicated by the purple box and kit supplied standards by the green 
box. 
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 3.2.4 Standard curve determination 
 As neither the standard curve type nor curve fit equation is given in the Bio-Rad 
Platelia Rabies Kit II ELISA kit insert or via the proprietary Excel results worksheet, the 
concentration of the samples produced by each standard curve type (see Equation 3. Gen5 
Polynomial Curve, Equation 4. Gen5 Spline Curve, and Equation 5. Gen5 Non-linear 
Curve; see also, Figure 8. Gen5 Generated Standard Curve for Point to Point Fit, Figure 
9. Gen5 Generated Standard Curve for Polynomial Fit, Figure 10. Gen5 Generated 
Standard Curve for Spline Fit, and Figure 11. Gen5 Generated Standard Curve for Non-
Linear Fit) offered by the Gen5 software were compared against the concentration 
produced by the Bio-Rad Excel results worksheet for the best fit using Equation 2. 
Percent Recovery where the Experimental Value is equal to the results obtained from 
using the anti-IgG conjugate coupled with a human IgG standard prepared internally 
(KAM-1) as the standard curve and the Expected Value is equal to the results obtained 
from using the Protein A conjugate supplied by the kit and Bio-Rad proprietary 
calculations. 
 
Equation 2. Percent Recovery 
%R=(Experimental Value/Expected Value) x 100 
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Figure 8. Gen5 Generated Standard Curve for Point to Point Fit 
 
 
 
Figure 9. Gen5 Generated Standard Curve for Polynomial Fit 
 
 
 
 
 
 
Equation 3. Gen5 Polynomial Curve 
Y=C*X^2+B*X+A 
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StdCurve_Spline
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Figure 10. Gen5 Generated Standard Curve for Spline Fit 
 
 
 
 
 
Equation 4. Gen5 Spline Curve 
R2 value is set to a value of 1 
 
 
 
 
 
Figure 11. Gen5 Generated Standard Curve for Non-Linear Fit 
 
 
 
 
Equation 5. Gen5 Non-linear Curve 
Y = (A-D)/(1+(X/C)^B) + D 
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Based upon the results in Table 5. IgG to Prot A %R (Based on Results in 
EU/mL) below, it was determined that both the Point to Point and the Non-Linear 
standard curves had the tightest fit upon statistical analysis of the results (EU/mL) 
compared to the Bio-Rad Excel results worksheet generated results (also EU/mL).  All 
curves produced similar averages.  The non-linear curve fit type produced a tighter range 
and had a correlation coefficient of 1 where the Polynomial had a value of .927.  Non-
linear was chosen for use in the IgM and IgG assays due to the above findings and the 
basis that there is a curve fit equation provided that can be used to check the 
quantification of the antibody in each sample by solving for X, X = C*([(A-D)/(y-
D)]^(1/B)-1), where y equals the delta OD reading value. 
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Table 5. IgG to Prot A %R (Based on Results in EU/mL) 
 
% R=(Experimental Value/Protein A Value)*100  
Sample 
ID: 
Non-
Linear
Polynomial
Point To 
Point
Spline
Sample 
ID: 
Non-
Linear
Polynomial
Point To 
Point
Spline
RAE-1 RAE-25
RAE-2 56.12% 71.67% 58.39% 58.39% RAE-26
RAE-3 60.20% 83.73% 60.88% 60.88% RAE-27 55.67% 73.23% 59.39% 59.39%
RAE-4 106.49% 60.71% 121.58% 121.58% RAE-28 77.41% 95.98% 79.13% 79.13%
RAE-5 86.69% 62.12% 94.15% 94.15% RAE-29
RAE-6 RAE-30
RAE-7 RAE-31
RAE-8 64.33% 0.00% 63.85% 63.85% RAE-32
RAE-9 63.59% 36.54% 63.53% 63.53% RAE-33
RAE-10 54.62% 43.26% 54.26% 54.26% RAE-34 71.79% 102.07% 76.07% 76.07%
RAE-11 69.86% 45.58% 79.77% 79.77% RAE-35
RAE-12 RAE-36
RAE-13 RAE-37 81.90% 68.52% 82.38% 82.38%
RAE-14 RAE-38 50.42% 64.37% 52.36% 52.36%
RAE-15 82.96% 82.96% 82.96% 82.96% RAE-39
RAE-16 29.22% 41.39% 29.81% 29.81% RAE-40
RAE-17 16.65% 14.81% 16.77% 16.77% RAE-41 52.61% 69.06% 54.55% 54.55%
RAE-18 31.67% 27.76% 33.74% 33.74% RAE-42
RAE-19 RAE-43
RAE-20 RAE-44 74.43% 78.91% 76.75% 76.75%
RAE-21 82.20% 64.79% 82.55% 82.55% RAE-45 56.15% 66.88% 61.37% 61.37%
RAE-22 65.80% 86.10% 68.27% 68.27% RAE-55
RAE-23 38.90% 41.86% 44.73% 44.73% RAE-56 50.00% 50.00% 50.00% 50.00%
RAE-24 55.09% 57.33% 63.20% 63.20% RAE-57 46.69% 65.91% 51.39% 51.39%
RAE-58 82.28% 103.56% 85.71% 85.71%
R
2
 Value 1 0.927 NA 1 Avg 0.62 0.61 0.65 0.65
Min 0.17 0.00 0.17 0.17
Max 1.06 1.04 1.22 1.22
Median 0.60 0.65 0.63 0.63
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***</= results excluded due to large difference in the lower limit of quantitation of </= 0.125 for Protein A and </= 0.625 for 
IgG
***
***
Percent Recovery of patient sample titer results using: KAM-1 human rabies immunoglobulin (HRIG) 
purified IgG plasma standard diluted as per the kit recommended 1:100 followed by 1:2 serial dilutions 
in establishment of the quantitative IgG standard curve paired with anti-IgG HRP conjugate at a 
dilution of 1:4800 utilizing Gen5 software standard curve types compared to R4b kit standard curve 4 
EU/mL positive sample paired with Protein A HRP conjugate at a dilution of 1:10 and Bio-Rad 
proprietary calculations.  Red boxes correspond to the Gen5 Non-linear curve as the best fit compared 
to the Bio-Rad results based on comparing the average value, range, and (R2) correlation coefficient. 
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 3.3 IgM ELISA Materials and Methods 
With the selection of the best curve fit alongside the previous proof of concept, 
the necessary groundwork is laid for moving into IgM assay development.  Assessment 
beginning with selection of the most appropriate standard curve sample and the best fit 
for anti-IgM HRP working dilution for use in quantifying anti-rabies IgM in human sera 
is outlined below. 
 
 3.3.1 Kit 
Same as assayed under section 3.2.1 Protein A ELISA Materials & Methods, with 
a secondary anti-human IgM HRP conjugate (Sigma Cat# A6907) used to detect IgM in 
place of the kit HRP Protein A.  Version 881179 – 2015/06 kit instructions were followed 
to obtain the titer value in EU/mL which were calculated by comparison of the sample 
optical density reading against a standard curve of the most suitable positive sample 
demonstrated to have IgM antibodies. 
 
 3.3.2 Determination of IgM conjugate concentration and standard curve 
sample 
 Anti-human IgM HRP conjugate was initially tested in duplicate using serial 1:2 
dilutions beginning at 1:1600 continuing until a 1:100,000 dilution was achieved.  RAE-2 
was selected as the sample representing IgM antibody based on a 14 DPV collection and 
previous results in the proof of concept study performed in 2016.  RAE-2 at the assay 
1:100 dilution was utilized as the primary antibody and compared to the Protein A assay 
and standard curve results in the presence of each IgM conjugate serial dilution.  IgM 
conjugate was also tested in the absence of rabies antibody at a dilution of 1:12,500, 
comparable to that of the lot recommended 1:10,000, to assess any false reactivity or 
background reaction to the rabies antigen coated wells.  Abnormally high coefficients of 
variation (%CV) are a result of probable conjugate instability or a prozone effect for the 
1:6400 and 1:125,000 anti-IgM conjugate serial dilutions, see Table 6. 
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Table 6. IgM Conjugate Dilution Replicates 
 
 
Further analysis included comparing the Protein A results against samples tested 
and making the determination to test low draw date samples (less than DPV 21) to 
maximize the likelihood of capturing IgM alone that displayed results close to the delta 
4.000 optical density value to mimic the R4b kit supplied standard curve control.  The 
goal in standard curve determination is to ensure that the negatives are negative, positives 
are positive, and the curve has a clear delineation between each point.  RAE-2, -8, -21, -
37 were the starting samples based on the above criteria and as a comparison of the 
Protein A results were all </= 0.125 for sample RAE-2 and 0.007 OD for kit negative control R3
Sample 
ID:
IgM OD: Average:
Standard 
Deviation:
%CV:
RAE-2 0.19 0.201 0.011 5.24%
RAE-2 0.211
RAE-2 0.09 0.099 0.009 9.09%
RAE-2 0.108
RAE-2 0.058 0.068 0.010 14.07%
RAE-2 0.077
RAE-2 0.053 0.045 0.008 19.10%
RAE-2 0.036
RAE-2 0.021 0.020 0.001 5.00%
RAE-2 0.019
RAE-2 0.015 0.015 0.001 3.45%
RAE-2 0.014
RAE-2 0.011 0.011 0.000 0.00%
RAE-2 0.011
Sample 
ID:
IgM OD: Average:
Standard 
Deviation:
%CV:
None 0.009 0.008 0.001 12.50%
None 0.035 0.021 0.014 66.67%
Conjugate Dilution:
1:3200
1:3200
1:1600
1:1600
1:12500
Empty Well
1:100000
1:100000
1:50000
1:50000
Conjugate Dilution:
1:25000
1:25000
1:12500
1:12500
1:6400
1:6400
Anti-IgM conjugate titrations as the secondary against RAE-2 a day 14 post vaccination serum sample 
(that also had below the limit of detection result via the Protein A IgG assay) used to better establish 
the appropriate working dilution of anti-IgM for the purposes of detecting anti-rabies IgM in human 
serum.  Empty wells and wells containing conjugate only were also assessed to assay potential 
background from the conjugate that could lead to a false positive reaction.  These values were assessed 
based upon the kit supplied R3 negative average optical density (OD) value of 0.007.  Statistical 
analysis including comparing the coefficient of variation contributed to the assessment of establishing 
the 1:1000 working dilution for the anti-IgM conjugate. 
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RFFIT result as compared to the previously tested IgM samples in the proof of concept 
testing completed in 2016. 
IgM conjugate dilution of 1:8,000 was chosen as the starting point for the S1-S6 
standard curve due to a low %CV (a value of 30% for percentage coefficient of variation 
is the upper level for acceptable precision for ELISA validation) and to keep close to the 
manufacturer’s recommended dilution of 1:10,000.  RAE-21 displayed the most 
appropriate curve fit under these conditions and will be tested at alternate conjugate 
dilutions at higher concentrations to obtain an upper limit closer to the 4.000 delta OD 
value (see Figure 12). IgM Standard Curve Starting Point).  Dilutions for the Rb4 kit 
supplied 4.0 EU/mL sample were followed in generation of the standard curves for all 
IgM samples and provided as a reference in IgM Figure 12 and 13 below. 
For all graphical representations of standard curves going forward, the X-axis 
(horizontal) corresponds to the dilution of the sample or the estimated concentration in 
EU/mL if known, and the Y-axis (vertical) correspond to the delta OD value obtained 
from the calibrated microplate reader. 
 
Figure 12. IgM Standard Curve Starting Point 
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Representative samples utilized in the establishment of the quantitative IgM standard curve assayed 
against varying dilutions of anti-IgM HRP conjugate. Sample RAE-21 against anti-IgM conjugate at a 
working dilution of 1:10,000 displayed the most appropriate curve fit compared to the R4b kit supplied 
standard curve. 
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Sample RAE-21 against conjugate dilutions of 1:3200, 1:4800, 1:7200, and 
1:10800 resulted in the finding that the higher concentration of conjugate did raise the 
upper limit to a value of approximately 1.800 delta OD while also holding the appropriate 
curve fit and not causing a prozone shape (see Figure 13).   
IgM conjugate dilutions of 1:1000, 1:1500, 1:2250, and 1:3375 were then assayed 
against sample RAE-21 and found to be appropriate for standard curve fit.  A dilution 
concentration of 1:1000 was chosen as the most appropriate for this IgM conjugate lot 
because of the trend of a lower %CV for higher concentrations of conjugate (from Table 
6. IgM Conjugate Dilution Replicates), and the upper limit value being close to 4.000 for 
the delta OD value (see Figure 13).  Higher concentrations of conjugate were not pursued 
as there is normal assay variation that can result in the shifting of the standard curve delta 
OD value and could cause a shift to a value much greater than the targeted upper limit of 
the assay. 
 
Figure 13. RAE-21 IgM Concentration Test 
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Sample RAE-21 against serial 1:2 dilutions of anti-IgM conjugate at a starting dilution of 1:10,800 to 
establish the most appropriate IgM assay conjugate working dilution.  RAE-21 paired with anti-IgM 
HRP conjugate at a working dilution of 1:1000 was verified to be the most appropriate fit for purpose. 
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 3.3.3 Serum samples 
Same as assayed under section 3.1.2 RFFIT Materials & Methods, section Serum 
Samples. The focus for detecting IgM antibody were samples drawn on days 7 and 14. 
 
 3.3.4 Serological testing 
The indirect ELISA method, Bio-Rad Platelia Rabies Kit II ELISA (Marnes-la-
Coquette, France) was performed using the manual method per the manufacturer’s 
instructions.  A BioTek ELx808 microplate reader coupled with Gen 5 (version 2.06) 
software set to the estimated IgM standard value (as estimated from comparison of the 
RFFIT (IgM and IgG combined effect via virus inhibition as detected by the anti-N 
protein conjugate) and Protein A (IgG conjugate) ELISA assays) for quantitative titer 
results in EU/mL for each sample (IgM range: </= 0.25 to >/= 8 EU/mL), see Table 7.  
Samples producing results above the IgM upper level of quantitation (ULOQ) of >/= 8 
EU/mL were pre-diluted and retested to obtain an endpoint result within the quantitative 
range of each assay. RAE-2, -3, -8, -10, -16, -21, -22, and -37 were pre-diluted 1:10 using 
20 µL sample and 180 µL R6 diluent. 
 
Table 7. IgM ELISA Standard Curve Generation and Concentration 
 
 
Quantification 
standards
Concentrations obtained by serial 
dilutions of the RAE-21 Positive 
control
S6 RAE-21 diluted to 1:100 8 EU/mL
S5 S6 diluted to 1:2 4 EU/mL
S4 S5 diluted to 1:2 2 EU/mL
S3 S4 diluted to 1:2 1 EU/mL
S2 S3 diluted to 1:2 0.5 EU/mL
S1 S2 diluted to 1:2 0.25 EU/mL
RAE-21 IgM standard curve sample dilution scheme.  An 8 EU/mL upper limit value was estimated 
from the RFFIT (IgM + IgG) titer results compared to Protein A ELISA (IgG) titer results.  
Quantification standard concentration estimated from serial 1:2 dilutions of the 8 EU/mL upper limit 
value. 
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Table 8. IgM ELISA Titer Results 
 
 
As expected, the day 0 samples display results below the limit of quantitation (</ 
0.250) and the EU/mL titer result increases after each early vaccination with a decrease 
of antibodies near the day 28 post vaccination draw date indicating the possibility of the 
timing for class switching to IgG antibody production, see Table 8.  The internal 
standards (Ref2017, MMP-4, 0.5Ref2017, and FBS) all displayed below the limit of 
detection values and do not provide the added interassay validity between the initial assay 
and subsequent assay runs to include the pre-dilutions for endpoint titration.  In addition, 
the kit supplied standards (R3, R4a, and R4b) all produce </= 0.250 titer results as 
expected in quantifying IgM as these are IgG specific controls. 
Sample 
ID:
DPV:
Results 
(EU/mL):
Sample 
ID:
DPV:
Results 
(EU/mL):
Sample 
ID:
DPV:
Results 
(EU/mL):
RAE-1 0 </= 0.250 RAE-21 14 7.04 RAE-41 31 5.02
RAE-2 14 14.39 RAE-22 21 7.96 RAE-42 0 </= 0.250
RAE-3 21 16.38 RAE-23 28 3.29 RAE-43 7 0.36
RAE-4 28 6.69 RAE-24 42 2.28 RAE-44 21 2.84
RAE-5 42 3.32 RAE-25 0 </= 0.250 RAE-45 42 1.04
RAE-6 0 </= 0.250 RAE-26 7 1.17 RAE-55 0 </= 0.250
RAE-7 7 1.64 RAE-27 21 6.23 RAE-56 7 </= 0.250
RAE-8 14 8.22 RAE-28 28 2.90 RAE-57 14 2.23
RAE-9 21 5.73 RAE-29 0 </= 0.250 RAE-58 28 1.60
RAE-10 28 13.00 RAE-30 7 </= 0.250 HRIG HRIG </= 0.250
RAE-11 42 4.68 RAE-31 14 1.23 Ref2017 Ref2017 </= 0.250
RAE-12 0 </= 0.250 RAE-32 21 1.74 MMP-4 MMP-4 </= 0.250
RAE-13 7 </= 0.250 RAE-33 28 1.14 0.5Ref2017 0.5Ref2017 </= 0.250
RAE-14 10 0.38 RAE-34 42 0.91 FBS FBS </= 0.250
RAE-15 14 2.65 RAE-35 0 </= 0.250 R3 R3 </= 0.250
RAE-16 21 5.22 RAE-36 0 </= 0.250 R3 R3 </= 0.250
RAE-17 28 2.33 RAE-37 16 8.03 R4a R4a </= 0.250
RAE-18 42 1.25 RAE-38 31 3.63 R4a R4a </= 0.250
RAE-19 0 </= 0.250 RAE-39 0 </= 0.250 R4b R4b </= 0.250
RAE-20 7 0.69 RAE-40 16 </= 0.250 R4b R4b </= 0.250
Indirect enzyme-linked immunosorbent assay (ELISA) endpoint titer results expressed in EU/mL 
(Equivalent Units) for all samples using anti-IgM HRP at a dilution of 1:1000 as the secondary 
conjugate.  Below limit of quantitation results display as “</= 0.250” and any samples with titers > 8.0 
(the assay upper limit) were pre-diluted prior to following the manufacturer 1:100 assay dilution.  
Samples RAE-1 through RAE-5, as indicated by the red box (also denoted by shading), correspond to a 
single patient for all draw dates (expressed in days post vaccination (DPV).  RAE-35 corresponds to 
pooled negative samples. Internal standards are indicated by the purple box and kit supplied standards 
by the green box. 
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Dilution linearity was tested to assess the accuracy of this selection of the 
standard curve sample RAE-21 and the anti-IgM conjugate dilution in generating quality 
and reliable titer results.  Low (RAE-15), medium (RAE-5), and high (RAE-21) IgM 
samples were chosen to represent the assay range.  Trend lines accurately depict the 
starting value, halving of that value due to serial 1:2 dilution, and the expected shape of 
the curve for all three samples included in this assessment see Figure 14.  Reproducibility 
holds within the <30% CV between the initial test results and the neat sample result for 
the linearity test as well.  RAE-15 has a lower percent recovery due limited data points 
corresponding to values above the upper limit of detection (</= 0.250) for comparison to 
the theoretical value.  This is considered acceptable with the overall actual and theoretical 
values being well above the 0.5 EU/mL titer value that is considered protective against 
rabies. 
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Figure 14. IgM Dilution Linearity Test 
 
 
 3.4 IgG ELISA Materials and Methods 
The selection of the best curve fit methodology for anti-IgM alongside the 
previous proof of concept testing utilizing R4b 4.0 EU/mL positive control, the necessary 
groundwork is laid for moving into further IgG assay development.  Assessment 
Sample 
ID:
DPV:
Actual 
Results 
(EU/mL):
Theoretical 
Results 
(EU/mL):
%R
RAE-4 28 6.69 6.20 92.63%
RAE-15 14 2.65 2.03 76.55%
RAE-21 14 7.04 6.30 89.42%
RAE-4 y = 0.0803x2 - 1.4209x + 6.2345
R² = 0.9994
RAE-15 y = 0.0818x2 - 0.9824x + 2.7781
R² = 0.9564
RAE-21 y = 0.2611x2 - 3.2096x + 9.4318
R² = 0.95
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High (RAE-21), medium (RAE-4), and low (RAE-15) titer (EU/mL) value samples were serially 
diluted 1:2 and all dilutions were assayed via the anti-IgM ELISA using the 1:1000 conjugate working 
dilution to determine the dilution linearity for the assay.  Actual results (all values obtained from each 
point on the linearity curve) were compared to the theoretical result for that sample and percent 
recovery (%R) calculated using %R=(Actual/Theoretical) x 100.  Curve fit equations included for each 
sample indicated by the Poly. (Sample) curve and included equations. 
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beginning with selection of the most appropriate standard curve sample and the best fit 
for anti-IgG HRP working dilution for use in quantifying anti-rabies IgG in human sera is 
outlined below. 
 
 3.4.1 Kit 
Same as assayed under section 3.2.1 Protein A ELISA Materials & Methods, 
section Kit with a secondary anti-human IgG HRP conjugate (Sigma Cat# A0170) used 
to detect IgG in place of the kit HRP Protein A conjugate.  Version 881179 – 2015/06 kit 
instructions were followed to obtain the titer value in EU/mL which were calculated by 
comparison of the sample optical density reading against a standard curve of a positive 
plasma sample found to be suitable for accurately detecting IgG. 
 
 3.4.2 Determination of IgG conjugate concentration and standard curve 
sample 
 Anti-human IgG HRP conjugate was tested in duplicate using serial 1:2 dilutions 
beginning at 1:1600 continuing until a 1:100,000 dilution was achieved.  RAE-5 was 
selected as the primary IgG antibody due to a DPV value of 42 and the Protein A ELISA 
result and then used at the assay 1:100 dilution and compared to the Protein A assay and 
standard curve results in the presence of each anti-IgG conjugate serial dilution.  Anti-
IgG conjugate was also tested in the absence of rabies antibody at a dilution of 1:50,000, 
similar to that of the lot recommended 1:60,000, to assess any false reactivity or 
background reaction to the rabies antigen coated wells (see Table 9).    
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Table 9. IgG Conjugate Dilution Replicates 
 
 
R4b was initially utilized as the IgG standard curve sample as compared to the 
previous proof of concept testing completed in 2016.  A 1:60,000 (manufacturers 
recommended) and a 1:10,000 dilution were chosen as the starting points for the S1-S6 
standard curve due to a low %CV (a 30% %CV is the upper level for acceptable precision 
for ELISA validation) dilution of anti-IgG conjugate were prepared and tested against the 
R4b generated standard curve in duplicate. 
Protein A results were all 0.164 for sample RAE-5 and 0.007 OD for kit negative control R3
Sample 
ID:
IgG OD: Average:
Standard 
Deviation:
%CV:
RAE-5 0.348 0.354 0.006 1.56%
RAE-5 0.359
RAE-5 0.277 0.284 0.006 2.29%
RAE-5 0.29
RAE-5 0.194 0.210 0.016 7.62%
RAE-5 0.226
RAE-5 0.13 0.127 0.004 2.77%
RAE-5 0.123
RAE-5 0.072 0.075 0.003 3.36%
RAE-5 0.077
RAE-5 0.048 0.047 0.001 2.13%
RAE-5 0.046
RAE-5 0.025 0.028 0.003 10.71%
RAE-5 0.031
Sample 
ID:
IgG OD: Average:
Standard 
Deviation:
%CV:
None 0.007 0.007 0.000 0.00%
None 0.016 0.012 0.005 39.13%
1:3200
1:50000
Conjugate Dilution:
1:6400
1:6400
1:12500
1:12500
1:25000
1:25000
1:50000
1:50000
1:100000
1:100000
Empty Well
1:3200
Conjugate Dilution:
1:1600
1:1600
Anti-IgG conjugate titrations as the secondary against RAE-5 a day 42 post vaccination serum sample 
(that theoretically would contain IgG alone and had an above the limit of detection results on the 
Protein A ELISA) used to better establish the appropriate working dilution of anti-IgG for the purposes 
of detecting anti-rabies IgG in human serum.  Empty wells and wells containing conjugate only were 
also assessed to assay potential background from the conjugate that could lead to a false positive 
reaction.  These values were assessed based upon the kit supplied R3 negative average optical density 
(OD) value of 0.007.  Statistical analysis including comparing the coefficient of variation contributed 
to the assessment of establishing the 1:4800 working dilution for the anti-IgG conjugate. 
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Curve results and the upper limit of 0.700 delta OD for the 1:60,000 dilution and 
1.200 delta OD for the 1:10,000 dilution in Figure 15. R4b Standard Curve + IgG 
Conjugate lead to the need for further analysis.  Comparing the Protein A results against 
samples tested and making the determination to test high draw date samples (greater than 
or equal to DPV 21) to maximize the likelihood of capturing IgG alone that also 
displayed results close to the 4.000 delta OD value to mimic the R4b kit supplied 
standard curve control was the next step.  RAE-23 was selected as the most appropriate 
starting sample for creation of the IgG standard curve based on the above criteria and 
comparison of the RFFIT and Protein A ELISA endpoint titer results. 
 
Figure 15. R4b Standard Curve + IgG Conjugate 
 
 
Figure 16. RAE-23 Standard Curve + IgG Conjugate shows curve results for the 
1:45,000, 1:4800, and 1:3200 dilutions.  Further experiments were needed to match the 
best fit compared to the Protein A curve results due to a prozone reaction with a 1.600 
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Kit supplied R4b 4 EU/mL positive standard utilized in the establishment of the quantitative IgG 
standard curve assayed against varying dilutions of anti-IgG HRP conjugate. R4b against anti-IgG 
conjugate at a working dilution of 1:4800 displayed the most appropriate curve fit compared to the R4b 
kit supplied standard curve against Protein A conjugate. 
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delta OD for the 1:45,000 dilution.  A stronger conjugate dilution is necessary to obtain a 
4.000 delta OD value for the S6 standard curve sample against IgG.  RAE-23 at the 
1:4800 conjugate dilution shows an ideal curve fit when compared to the Protein A R4b 
result and will continue to be the sample of choice for the anti-human IgG assay curve. 
 
Figure 16. RAE-23 Standard Curve + IgG Conjugate 
 
 
Samples S6 and S5 were tested to assess the presence of a similar prozone response as in 
Figure 17. RAE-23 S6S5 Standard Curve Prozone Test the secondary antibody were 
added to each S6 and S5 sample in duplicate.  Conjugate dilutions of 1:3200 and 1:4800 
showed an upward curve trend between those two samples closest to the target delta OD 
value of 4.000. 
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Representative samples (RAE-23 a day 28 post vaccination sample found to be the most appropriate 
shown in the figure) utilized in the establishment of the quantitative IgG standard curve assayed against 
varying dilutions of anti-IgG HRP conjugate. Sample RAE-23 against anti-IgG conjugate at a working 
dilution of 1:4800 displayed the most appropriate curve fit compared to the R4b kit supplied standard 
curve. 
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Figure 17. RAE-23 S6S5 Standard Curve Prozone Test 
 
 
Next, all standard curve samples (S1-S6) were assayed in duplicate against the 
two conjugate dilutions (1:3200 and 1:4800) found to meet the criteria in the search for 
an ideal standard curve upper limit delta OD value.  The dilution of 1:4800 was chosen as 
the most appropriate for this lot of anti-IgG conjugate based on the above and the %CV 
trend of values meeting the <30% for higher concentrations of conjugate. Higher 
concentrations of conjugate in the 1:3200 to 1:4800 range were not pursued as there is 
normal assay variation that can result in the shifting of the standard curve delta OD value 
and could cause a shift to a value much greater than the target. 
As the day 28 post vaccination RAE-23 sample most probably contains residual 
IgM antibody another internal standard utilized during plasma product testing via the 
RFFIT method was sought out as the most appropriate fit for use in the generation of an 
IgG quantification standard.  KAM-1 (HRIG) was next assessed as a more appropriate 
standard for use as the curve on the basis that the value (20.00 IU/mL) is known (defined 
by RFFIT) and that it is a purified IgG only containing sample.  This ensured that no false 
reactivity against any potential remaining IgM in the sample would alter the IgM to IgG 
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Quantification standards S6 and S5 for RAE-23 were assayed against varying dilutions of anti-IgG 
HRP conjugate to identify other dilutions producing prozone reactions such as RAE-23 against ant-IgG 
at a working dilution of 1:45,000 from the previous Figure 10. 
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ratio and results would be unequivocally based on IgG alone.  S1-S6 was tested undiluted 
(“neat”) and at a 1:5, 1:50, and 1:50,000 dilution (theoretical value of the 1:50 dilution 
upper limit is 4.0 EU/mL) to determine the best curve fit from this high titer sample.  As 
shown in Figure 18, KAM-1 Standard Curve Comparison, the undiluted sample produced 
both the target delta OD value and also appropriate standard curve shape and was used as 
the final standard curve in the assessment of IgG titer in this study.  
 
Figure 18. KAM-1 Standard Curve Comparison 
 
 
 3.4.3 Serum samples 
Same as assayed under section 3.1.2 RFFIT Materials & Methods, section Serum 
Samples.  The focus for detecting IgG antibody was day 21, 28, 35, and when present 42. 
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A known purified IgG only containing human rabies immunoglobulin standard (HRIG), KAM-1, 
utilized at varying pre-dilutions due to the known concentration of 20 EU/mL was used in the 
establishment of the quantitative IgG standard curve assayed against the 1:4800 working dilution of 
anti-IgG HRP conjugate. KAM-1 as per the manufacturers 1:100 followed by 1:2 serial dilutions 
(indicated by the “Neat” designation) against anti-IgG conjugate working dilution of 1:4800 displayed 
the most appropriate curve fit compared to the R4b kit supplied standard curve against Protein A 
conjugate. 
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 3.4.4 Serological testing 
The indirect ELISA method, Bio-Rad Platelia Rabies Kit II ELISA (Marnes-la-
Coquette, France) was performed using the manual method per the manufacturer’s 
instructions with the anti-human IgG conjugate substitution made.  A BioTek ELx808 
microplate reader coupled with Gen 5 (version 2.06) software set to the appropriate IgG 
standard curve values (as compared against RFFIT and Protein A ELISA) for quantitative 
titer results in EU/mL for each sample (IgG range: </= 0.625 to >/= 20 EU/mL), see 
Table 10.  Samples producing results above the IgG standard upper level of quantitation 
(ULOQ) of >/= 20 EU/mL were pre-diluted and retested to obtain an endpoint result 
within the quantitative range of each assay. 
 
Table 10. IgG ELISA Standard Curve Generation and Concentration 
 
 
 
 
 
Quantification 
standards
Concentrations obtained by serial 
dilutions of the KAM-1 Positive 
control
S6 KAM-1 diluted to 1:100 20 EU/mL
S5 S6 diluted to 1:2 10 EU/mL
S4 S5 diluted to 1:2 5 EU/mL
S1 S2 diluted to 1:2 0.625 EU/mL
S3 S4 diluted to 1:2 2.5 EU/mL
S2 S3 diluted to 1:2 1.25 EU/mL
KAM-1 IgG standard curve sample dilution scheme.  A 20 EU/mL upper limit value known from the 
RFFIT and Protein A ELISA titer results.  Quantification standard concentration estimated from serial 
1:2 dilutions of the 20 EU/mL upper limit value. 
41 
Table 11. IgG ELISA Results 
 
 
As expected, the day 0 samples display results below the limit of quantitation (</ 
0.625) and the EU/mL titer result increases after each early vaccination with a slight 
decrease and stabilization of antibodies near the day 42 post vaccination draw date, see 
Table 11.  A significant increase in titer occurs between day 21 to day 28 for most 
patients indicating the possibility of the timing for class switching from IgM to IgG 
antibody production.  The internal standards (Ref2017, MMP-4, 0.5Ref2017, and FBS) 
all correspond to the expected values (except MMP-4 which has a theoretical value below 
the </= 0.625 lower limit of the IgG assay) to provide the interassay validity between the 
initial assay and subsequent assays runs to include the pre-dilutions for endpoint titration.  
Sample 
ID:
DPV:
Results 
(EU/mL):
Sample 
ID:
DPV:
Results 
(EU/mL):
Sample 
ID:
DPV:
Results 
(EU/mL):
RAE-1 0 </= 0.625 RAE-21 14 1.91 RAE-41 31 3.74
RAE-2 14 3.417 RAE-22 21 3.52 RAE-42 0 </= 0.625
RAE-3 21 4.27 RAE-23 28 15.38 RAE-43 7 </= 0.625
RAE-4 28 19.14 RAE-24 42 13.86 RAE-44 21 2.93
RAE-5 42 20.58 RAE-25 0 </= 0.625 RAE-45 42 9.46
RAE-6 0 </= 0.625 RAE-26 7 </= 0.625 RAE-55 0 </= 0.625
RAE-7 7 </= 0.625 RAE-27 21 8.70 RAE-56 7 </= 0.625
RAE-8 14 1.53 RAE-28 28 8.478 RAE-57 14 8.86
RAE-9 21 2.06 RAE-29 0 </= 0.625 RAE-58 28 3.25
RAE-10 28 15.33 RAE-30 7 </= 0.625 HRIG HRIG 18.70
RAE-11 42 18.37 RAE-31 14 0.27 Ref2017 Ref2017 30.25
RAE-12 0 </= 0.625 RAE-32 21 1.18 MMP-4 MMP-4 </= 0.625
RAE-13 7 </= 0.625 RAE-33 28 </= 0.625 0.5Ref2017 0.5Ref2017 0.19
RAE-14 10 </= 0.625 RAE-34 42 5.85 FBS FBS </= 0.625
RAE-15 14 1.38 RAE-35 0 </= 0.625 R3 R3 </= 0.625
RAE-16 21 4.85 RAE-36 0 </= 0.625 R3 R3 </= 0.625
RAE-17 28 11.14 RAE-37 16 2.38 R4a R4a 0.46
RAE-18 42 18.57 RAE-38 31 13.55 R4a R4a 0.46
RAE-19 0 </= 0.625 RAE-39 0 </= 0.625 R4b R4b 5.93
RAE-20 7 </= 0.625 RAE-40 16 </= 0.625 R4b R4b NA
Indirect enzyme-linked immunosorbent assay (ELISA) endpoint titer results expressed in EU/mL 
(Equivalent Units) for all samples using anti-IgG HRP at a dilution of 1:4800 as the secondary 
conjugate.  Below limit of quantitation results display as “</= 0.625” and any samples with titers > 
20.0 (the assay upper limit) were pre-diluted prior to following the manufacturer 1:100 assay dilution.  
Samples RAE-1 through RAE-5, as indicated by the red box (also denoted by shading), correspond to a 
single patient for all draw dates (expressed in days post vaccination (DPV).  RAE-35 corresponds to 
pooled negative samples. Internal standards are indicated by the purple box and kit supplied standards 
by the green box. 
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Also, the kit supplied standards (R3, R4a, and R4b) produce appropriate values against 
the expected as these are IgG specific controls. 
Dilution linearity was tested to assess the accuracy of the selection of the standard 
curve sample and the IgG conjugate dilution (Figure 19).  Low (RAE-16), medium 
(RAE-27), and high (RAE-10) IgG samples were chosen to represent the assay range.  
Trend lines accurately depict the starting value, halving of that value due to serial 1:2 
dilution, and the expected shape of the curve for all three samples included in this 
assessment.  Reproducibility holds within the <30% CV between the initial test results 
and the average of the 1:2 sample results for the linearity test. 
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Figure 19. IgG Dilution Linearity Test 
 
 
With development, evaluation, and establishment of each standard curve and 
conjugate working dilution, endpoint titers as a whole can be evaluated in determining 
the following: variability of immunoglobulin class switching between individuals, the 
specific timing of that switch, accurately predicting high versus low responder’s effective 
immune defense, and discovering the time point when affinity maturation occurs.   
Sample 
ID:
DPV:
Actual 
Results 
(EU/mL):
Theoretical 
Results 
(EU/mL):
%R
RAE-10 28 15.33 17.91 116.83%
RAE-16 21 4.85 4.30 88.66%
RAE-27 21 8.70 9.66 111.06%
RAE-10 y = 0.7054x2 - 8.6859x + 25.611
R² = 0.9404
RAE-16 y = 0.1601x2 - 1.947x + 5.5969
R² = 0.9731
RAE-27 y = 0.2859x2 - 3.6688x + 11.436
R² = 0.9822
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High (RAE-10), medium (RAE-27), and low (RAE-16) titer (EU/mL) value samples were serially 
diluted 1:2 and all dilutions were assayed via the anti-IgG ELISA using the 1:4800 conjugate working 
dilution to determine the dilution linearity for the assay.  Actual results (all values obtained from each 
point on the linearity curve) were compared to the theoretical result for that sample and percent 
recovery (%R) calculated using %R=(Actual/Theoretical) x 100.  Curve fit equations included for each 
sample indicated by the Poly. (Sample) curve and included equations. 
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Chapter 4 - IgM, IgG, Protein A Results and Discussion 
 
The results of the Protein A, IgM, IgG, and RFFIT as they compare for the RAE 
(Rabies Antibody ELISA) sample set both in table form and graphically were evaluated 
to make determinations of the immunological status and Ig stage in the response both on 
an individual level and for the population as a whole. 
 
 4.1 Results 
 Referring to the results in Table 12 below, as expected there was little to no 
antibody response with use of anti-IgM, anti-IgG, or Protein A conjugate at day zero of 
the pre-exposure prophylaxis (PrEP) rabies vaccination series.  Trends shown in 
subsequent tables and figures show that IgM is predominately the class of human 
immunoglobulins present in the early stages of the vaccine induced immune response, 
day 7-21 post vaccination.  Class switching to IgG can be seen in the increase in IgG 
versus IgM antibodies present in the serum samples after the day 28 time point.  An IgG 
response is detected primarily at day 21-42 post receipt of initial rabies virus vaccine. 
 Variation in anti-IgG and Protein A conjugate assays is due to the preferential 
binding of the protein A conjugate to the Fc portion of multi-species IgG and not binding 
all subclasses equally while anti-IgG conjugate has a higher binding affinity specifically 
towards human IgG .  Lower and upper limits of quantitation are variable dependent upon 
the standard curve linear range.  Of note, none of the current internal standards are 
appropriate for consideration in the validity of the IgM assay runs and standards will need 
to be reassessed to ensure interassay validity. 
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Table 12. Combined ELISA Results using Non-Linear Standard Curve 
 
 
Sample 
ID:
DPV:
IgM 
EU/mL
IgG 
EU/mL
Prot A 
EU/mL
Sample 
ID:
DPV:
IgM 
EU/mL
IgG 
EU/mL
Prot A 
EU/mL
RAE-1 0 </= 0.250 </= 0.625 </= 0.125 RAE-31 14 1.23 0.27 0.24
RAE-2 14 14.39 3.42 3.30 RAE-32 21 1.74 1.18 0.46
RAE-3 21 16.38 4.27 3.86 RAE-33 28 1.14 </= 0.625 0.55
RAE-4 28 6.69 19.14 13.84 RAE-34 42 0.91 5.85 3.92
RAE-5 42 3.32 20.58 13.02 RAE-36 0 </= 0.250 </= 0.625 0.20
RAE-6 0 </= 0.250 </= 0.625 </= 0.125 RAE-37 16 </= 0.250 </= 0.625 </= 0.125
RAE-7 7 1.64 </= 0.625 </= 0.125 RAE-38 31 8.03 2.38 1.46
RAE-8 14 8.22 1.53 1.05 RAE-39 0 3.63 13.55 9.23
RAE-9 21 5.73 2.06 1.56 RAE-40 16 </= 0.250 </= 0.625 </= 0.125
RAE-10 28 13.00 15.33 18.25 RAE-41 31 5.02 3.74 3.72
RAE-11 42 4.68 18.37 18.07 RAE-42 0 </= 0.250 </= 0.625 </= 0.125
RAE-12 0 </= 0.250 </= 0.625 </= 0.125 RAE-43 7 0.36 </= 0.625 </= 0.125
RAE-13 7 </= 0.250 </= 0.625 </= 0.125 RAE-44 21 2.84 2.93 1.94
RAE-14 10 0.38 </= 0.625 </= 0.125 RAE-45 42 1.04 9.46 9.62
RAE-15 14 2.65 1.38 0.75 RAE-55 0 </= 0.250 </= 0.625 </= 0.125
RAE-16 21 5.22 4.85 8.97 RAE-56 7 </= 0.250 </= 0.625 </= 1.25
RAE-17 28 2.33 11.14 7.47 RAE-57 14 2.23 8.86 6.92
RAE-18 42 1.25 18.57 27.57 RAE-58 28 1.60 3.25 2.19
RAE-19 0 </= 0.250 </= 0.625 </= 0.125 HRIG HRIG </= 0.250 18.70 14.44
RAE-20 7 0.69 </= 0.625 </= 0.125 Ref2017 Ref2017 </= 0.250 30.25 24.81
RAE-21 14 7.04 1.91 1.40 MMP-4 MMP-4 </= 0.250 </= 0.625 0.14
RAE-22 21 7.96 3.52 2.95 0.5Ref2017 0.5Ref2017 </= 0.250 0.19 0.39
RAE-23 28 3.29 15.38 16.62 FBS FBS </= 0.250 </= 0.625 </= 0.125
RAE-24 42 2.28 13.86 12.38 R3 R3 </= 0.250 </= 0.625 </= 0.125
RAE-25 0 </= 0.250 </= 0.625 </= 0.125 R3 R3 </= 0.250 </= 0.625 </= 0.125
RAE-26 7 1.17 </= 0.625 </= 0.125 R4a R4a </= 0.250 0.46 0.46
RAE-27 21 6.23 8.70 7.73 R4a R4a </= 0.250 0.46 0.45
RAE-28 28 2.90 8.48 6.42 R4b R4b </= 0.250 5.93 4.09
RAE-29 0 </= 0.250 </= 0.625 </= 0.125 R4b R4b </= 0.250 NA 3.93
RAE-30 7 </= 0.250 </= 0.625 </= 0.125
Indirect enzyme-linked immunosorbent assay (ELISA) endpoint titer results expressed in EU/mL 
(Equivalent Units) for all samples using anti-IgM HRP at a dilution of 1:1000 with RAE-21 as the 
standard curve, anti-IgG HRP at a dilution of 1:4800 with KAM-1 as the standard curve, and Protein A 
HRP at a dilution of 1:10 with R4b as the standard curve.  Limits of quantitation range from “</= 
0.250” to 8.0 for IgM, “</= 0.625” to 20 for IgG, and “</= 0.125” to 4.0 for Protein A.  Any samples 
with titers above the assay upper limit were pre-diluted prior to following the manufacturer 1:100 assay 
dilution.  Samples RAE-1 through RAE-5, as indicated by the red box (also denoted by shading), 
correspond to a single patient for all draw dates (expressed in days post vaccination (DPV).  Internal 
standards are indicated by the purple box and kit supplied standards by the green box. 
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Anti-IgG versus Protein A conjugate results show confidence in the accuracy of 
the anti-IgG conjugate detecting serum IgG antibody despite the minor variability 
between conjugates.  Curve results below show similar shape and values for both anti-
rabies detecting assays as expected since Protein A and anti-IgG conjugates bind 
primarily to the Fc portion of IgG antibodies.  However, Sigma (Cat# A0170) anti-IgG is 
a polyclonal antibody with specific binding for human samples making this conjugate 
more specific for use in human sera samples and having greater avidity towards this 
species versus the multi-species IgG Protein A binding ability.  Utilizing a purified IgG 
product, KAM-1, as the IgG standard curve increases the confidence that these results are 
quantifying IgG alone.  The IgM trend line also follows what is typically seen for the 
primary immune response to vaccination. 
Figure 20. Average ELISA Results Compared 
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Indirect enzyme-linked immunosorbent assay (ELISA) endpoint titer results expressed in EU/mL 
(Equivalent Units) were averaged for each draw date comparing anti-IgM HRP, anti-IgG HRP, and 
Protein A HRP secondary conjugates.  IgG and Protein A show comparable detection of IgG.  IgM 
follows the estimated immune reaction in response to vaccination of an increased value from day 7 to 
21 followed by the class switch to IgG between day 21 to 28 and decreasing IgM value. 
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The IgM to IgG ratio further solidifies the finding that IgM is predominately the 
primary response to vaccination or booster.  Graphically, the trend of increased IgM 
during the median sampling of day 14 and day 21 post vaccination for most subjects is 
clearly observed.  Variability is demonstrated between vaccine recipients regardless of 
the overall followed trend of IgM to IgG around the day 21 to 28 period.  Grouped patient 
samples demonstrate the wide range in variability between an individual’s response to 
vaccination. 
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Figure 21. IgM to IgG ELISA Ratio 
 
 
Long-lasting neutralization ability being predominately IgG related is proven 
through correlation of the increasing IgG ELISA results alongside increasing 
neutralization (RFFIT) titer values.  As proven for rabies virus in previous studies, it 
takes approximately 1 to 2 IgG molecules to neutralize three virion spikes versus only 1 
IgM molecule to neutralize up to ten rabies virion spikes for neutralization of 63% of the 
virus present [45].  This follows the structural reasoning that IgG is monomeric (can bind 
IgM to IgG indirect enzyme-linked immunosorbent assay (ELISA) endpoint titer results expressed in 
EU/mL (Equivalent Units) were calculated and plotted for each draw date comparing anti-IgM HRP, 
and anti-IgG HRP secondary conjugates.  IgM follows the estimated immune reaction in response to 
vaccination of an increased value from day 7 to 21 and in some instances day 28 followed by the class 
switch to IgG between day 21 to 28 and decreasing IgM value.  Vertical black lines separate between 
individual patient serum sets drawn at the designated days post vaccination.  The horizontal line 
designates the cutoff for a protective titer of 0.5 EU/mL. 
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up to two molecules) and IgM is pentameric and able to bind up to ten molecules.  Also 
of interest, during the same study, the threshold detected after the greatest neutralization 
effect occurred was 400 to 1000 IgG molecules per virion and approximately 100 
molecules of IgM [45].   RFFIT nucleoprotein conjugate accurately detects IgM levels of 
antibody next to neutralizing ability even though the predominately IgG response elicits a 
stronger neutralization titer value compared to IgM.  The smaller structural size allowing 
IgG to move across tissues, whereas IgM is structurally too large, is one of the reasons 
that IgG is present in larger quantities where long lasting neutralization is also present.  In 
the case of vaccination and booster, IgM will be produced in response to the viral 
antigens present in the administered vaccine that will quickly be replaced with IgG via 
class switching during the humoral immune response.  To more accurately quantify the 
IgM contribution to neutralizing ability aliquots of patient sera would need to undergo 
column purification with selection for the IgM-containing fraction and assayed on the 
Rapid Focus Fluorescent Inhibition Test (RFFIT) for endpoint titer values. 
In Figure 22 below, as expected, there is no detectable antibody at day 0 for all 
assay methods.  Day 7 post vaccination seemingly elicits an IgG response but this is 
explained by the difference in lower limits of detection due to the linear range differences 
in each assay (0.1 for RFFIT, 0.25 for IgM, and 0.625 for IgG). Assessing the need for a 
modified lower limit of detection for the IgG assay will need to be determined for 
accurately quantifying protection status at > 0.5 EU/mL as recommended by the 
Advisory Committee on Immunization Practices (ACIP).  Class switching from IgM to 
IgG is observed in the IgM data (yellow) as well as the specific timing of that switch 
(predominately DPV 21 to 28).  Rabies virus neutralizing antibodies (RVNA) correlate to 
long-lasting IgG evident after DPV 21 (purple coupled with linear).  Affinity maturation 
due to selection and clonal expansion for B-cells that class switch to produce highly 
neutralizing IgG clones are evident in both the RFFIT results (linear) and the IgG results 
(purple). 
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Figure 22. All Results Compared (RFFIT/IgM/IgG)
 
 
 4.2 Discussion 
Similar immune trends to the response to rabies vaccination are available for other 
human viral and bacterial infections.  Rotavirus displays a similar trend with IgM present 
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Indirect enzyme-linked immunosorbent assay (ELISA) endpoint titer results expressed in EU/mL 
(Equivalent Units) were calculated and plotted for each draw date comparing anti-IgM HRP, and anti-
IgG HRP secondary conjugates as well as comparing the neutralizing ability and contribution of each 
antibody to that neutralizing function via the rapid focus fluorescent inhibition test (RFFIT).  The 
horizontal line designates the cutoff for a protective titer of 0.5 EU/mL.  Class switching from IgM to 
IgG is visible in the IgM data (in yellow), as well as the specific timing of that switch (predominately 
DPV 21 to 28).  Rabies virus neutralizing antibody (RVNA) correlates to long-lasting IgG evident after 
DPV 21 (purple IgG coupled with linear RFFIT).  Affinity maturation due to clonal expansion of 
highly neutralizing IgG clones is displayed in both the RFFIT results (linear) and the IgG ELISA 
results (purple).  
International units (IU/mL) were calculated from the serum titer using the following formula: 
(Endpoint titer of test serum/ Endpoint titer of reference serum) X 2.0 IU/mL reference serum (a WHO 
standard).  Equivalent units (EU/mL) were calculated by comparison of the sample optical density 
reading against a Non-linear fit type standard curve of positive standards. 
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in the early collected serum samples and lower levels in the late infection stage collected 
serum samples [46–49].  IgG detection via ELISA and neutralization response were the 
same for rotavirus as well [49] which further confirms the response in the rabies IgG and 
RFFIT assays.  Antibody kinetics obtained via ELISA for hepatitis E virus show the 
typical pattern of quick increase in IgM with a seroconversion to IgG [50,51].  Enzyme 
immunoassays (EIA) were used to detect IgG against Epstein-Barr virus (EBV) and show 
the same trend of low IgG detected in newly infected patients and high in persons with 
reactivation of the virus or previous exposure to the virus [52].  IgM and IgG are detected 
at the same time in both reactivation and after initial infection [52] which follows the 
same immunological trend for rabies upon initial infection or vaccination followed by 
any booster.  Despite a few mixed findings in the co-presence of IgM and IgG in early 
stage infection of Treponema pallidum leading to Syphillis, it is clear that IgM is only 
present in early infection with IgG being the primary immunoglobulin detected in late 
infection [53–55].  ELISA (or a similar immunoassay) was the chosen method for each of 
the examples in determining the IgM versus IgG responses.  This method is quantitative, 
gives an objective value from a calibrated reader, is less labor intensive than similar in 
vitro methods, and has been shown to have similar specificity and sensitivity to the 
current gold standard methods of testing. 
By utilizing a wide variety of validation parameters in evaluating the use of the 
Bio-Rad Platelia Rabies II indirect ELISA kit for use in detecting IgG and IgM in human 
sera, conditions are optimized to detect, with confidence, the concentrations of both IgG 
and IgM for each sample and accurately determine the kinetics of the immune response to 
rabies vaccination.  Investigation of the immune reaction of each individual's response to 
vaccination has contributed to further our understanding of the variability of 
immunoglobulin class switching between individuals, the specific timing of that class 
switch from IgM to neutralizing IgG via clonal expansion through affinity maturation in 
the lymphoid tissue for these best fit immune cells.  It is the starting point in being able to 
accurately predict high versus low responder’s effective immune defense to better 
classify these individuals rabies protection status.  This data will also help guide future 
research of preventative and treatments options as well as guide further development of 
anti-rabies immunological assays. 
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 Future improvements  such as increased sample numbers would aid in 
determining trends of non-conformant patient samples such is the case with samples 
RAE-55 through RAE-57 collected from a single patient all showing lower titration 
values across sampling days.  Upon collection of the data from these subjects, further 
testing and analysis can be conducted on other factors involved in the immune response, 
for example cytokines, to better expand our knowledge of these individual’s atypical 
response to rabies vaccination.  This understanding would drive further research and 
development of more effective vaccines or vaccine schedules.  The increase in patients 
will allow for pooling appropriate samples for use as the IgM quantification standard for 
standard curve creation.  After validation of the pooled IgM standard further longevity 
would be achieved as well as longevity in the confidence in the IgM assay. 
After successful complete diagnostic validation of the Platelia Rabies II ELISA 
kit (parameters outlined in Chapter 5 below) with anti-IgM and anti-IgG secondary 
conjugates via the manual method, a partial validation can be completed utilizing the 
automated method by assessing precision and limits of quantification.  Further evaluation 
and validation would branch out into human plasma samples for analysis of the immune 
status of plasma donors and plasma products for post-exposure prophylaxis (PEP). 
As demonstrated, the modified rabies enzyme-immunosorbent assays (ELISAs) 
with anti-IgM or anti-IgG secondary conjugates paired with the appropriate standard 
curve samples are: quantitative, obtain an objective value from a microplate reader, are 
less labor intensive than similar methods such as the Rapid Focus Fluorescent Inhibition 
Test (RFFIT), and display similar specificity and sensitivity to the current gold standard 
methods of testing (RFFIT and Protein A ELISA).  Conditions are optimized to detect, 
with confidence, the concentrations of both IgM and IgG for each sample and accurately 
determine the kinetics of the immune response to rabies vaccination.   
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Chapter 5 - Future Direction 
A full diagnostic validation will be performed so that the IgM and IgG assays can 
be added to the repertoire of testing offered by the Kansas State Veterinary Diagnostic 
Laboratory (KSVDL) Rabies department.  Appropriate IgM internal standards need to be 
developed in order to further quantify the validity of each assay run and be able to 
effectively compare interassay data.  This will be achieved via the assessment of the 
appropriate pooling of the larger patient sampling outlined in the previous discussion 
section. 
 
 5.1 Assay Diagnostic Validation 
Once these values are established the next phase of validation will move forward.  
Primary parameters to test during the validation are as follows: repeatability, robustness, 
intermediate precision, accuracy/linearity, specificity, dilutability, limits of quantitation.  
Clinical Laboratory Improvement Amendments (CLIA), GMP, General Laboratory 
Practices (GLP), and International Conference on Harmonisation (ICH) standards will be 
closely followed during this evaluation as is the requirement for use in the Kansas State 
University Rabies Laboratory. 
 
 5.2 Proposed Validation Design 
Precision and repeatability will be measured by collecting one sample each that 
has known values that correspond to each dilution of the standard curve (0.25 to 8.00 
EU/mL for IgM and 0.625 to 20.00 EU/mL for IgG).  One sample for each EU/mL range 
will be selected, until each value has a representative sample and create at least 25 
aliquots to store at -80ºC pending analysis.  The assay will be performed on five different 
days with five replicates of each sample.  Data from each day will appear on different 
rows for calculation of mean value, standard deviation (SD), confidence value (%CV) to 
assess both the repeatability and intermediate precision of the assay. 
Robustness of temperature, time, and conjugate dilution will also be assessed.  
One sample for each of the EU/mL range values as per the diluted standards for 
quantitation will be used and run in duplicate for each parameter to test robustness.  
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Sample incubation temperature will be assayed at 37ºC±3ºC in six independent runs (one 
run for each degree ±37ºC).  Conjugate incubation temperature will be assayed at 
37ºC±3ºC in six independent runs (one run for each degree ±37ºC).  Substrate incubation 
time, as per the kit instructions, already has a wide range of +18ºC to +30ºC and will not 
be included in this robustness assessment.  Incubation time for samples will be assayed at 
60 minutes ± 5 minutes in 10 independent runs (one run for each minute ± the initial 60 
minute incubation time).  Incubation time for conjugate will be assayed at 60 minutes ± 5 
minutes in 10 independent runs (one run for each minute ± the initial 60 minute 
incubation time).  Incubation time for substrate will be assayed at 30 minutes ± 5 minutes 
in 10 independent runs (one run for each minute ± the initial 30 minute incubation time).  
Conjugate dilution robustness will be tested by assessing the test results for the 
representative samples at the appropriate calculated dilution ±10µL of undiluted 
conjugate into the appropriate unchanged volume of diluent (one run for each 1 µL ± the 
appropriate calculation volume for a total of 20 replicates). Data from each day will 
appear on different rows for calculation of mean value, standard deviation (SD), 
confidence value (%CV) to assess both the robustness parameters of the assay. 
Upper and lower levels of quantitation (analytical sensitivity) will be measured by 
the limits of quantification, dilution linearity, and parallelism.  Lower limit of 
quantification (LLOQ) will be determined by running 16 replicates of sample diluent (R6 
ready to use TRIS-EDTA buffer), calculating the mean SD, and determining the 
concentration at 3 SDs above the mean of the blank.  Next, samples with very low and 
very high concentrations of IgG and IgM will be analyzed in duplicate.  Calculating the 
average concentration and %CV will yield data points for a scatter plot of %CV as a 
function of concentration.  From the scatter plot, determining the lowest average level 
above where the %CV is <20% for most of the samples for the lower level and the 
highest average level below where the %CV is <20% for a majority of the samples for the 
upper level.   
Dilution linearity is measured to determine that a sample above the upper limit of 
quantification (ULOQ) can be diluted and yield a reliable and accurate result.  This will 
be achieved by spiking three RFFIT negative, undiluted human sera samples with KAM-
1 (IgG) and RAE-21 (IgM) at 100 to 1000 times the concentration at the ULOQ.  Serial 
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dilutions will be made in microcentrifuge tubes until the theoretical concentration is 
below the LLOQ; assay these dilutions in duplicate and factor in the dilution.  For the 
samples falling between the LLOQ and ULOQ, calculate the mean concentration, and the 
%Recovery for the theoretical concentrations.  All concentrations falling within the 
previously calculated LLOQ to ULOQ range are considered to be within the acceptance 
criteria for the precision.  Additionally, the signal versus the dilution factor will be 
researched to assess any suppression at concentrations that far exceed the ULOQ.  Using 
four samples with concentrations on the high end (must be lower than the ULOQ), make 
six two-fold dilutions in microcentrifuge tubes and assay in duplicate next to the samples 
tested neat.  To account for the dilution factor, calculate the %CV using readings from 
the neat samples and dilutions for each sample.  The %CV below 20% are considered 
adequate for demonstrating parallelism for this ELISA method. 
Human sera from subjects previously naïve will be vaccinated against rabies to be 
used to assess the diagnostic sensitivity and specificity of the assay.  Approved samples 
of known status via the RFFIT method and samples of unknown status (currently 
undergoing RFFIT testing) will be assayed in tandem.   
Lastly, sample stability has previously been investigated to assess 
immunoglobulin stability.  See “Validation Report of the Bio-Rad Platelia Rabies II for 
the measurement of Anti- Rabies Glycoprotein Antibodies-Sample Stability Evaluation”.  
 
 5.3 Assay Validation Results 
Calculations and comparisons will be completed between the control sera and 
samples of known and unknown vaccination status to determine each of the following: 
repeatability, robustness, analytical sensitivity and specificity, thresholds, diagnostic 
sensitivity and specificity, reproducibility and sample stability. 
 
 5.4 Validated Assay Uses 
After validation for diagnostic use, determining appropriate modifications to 
current rabies vaccination schedules can be achieved utilizing real world data from 
subjects receiving the current vaccination series.  Trends can be tracked with data 
collection occurring over time and sampling from a large population to more accurately 
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assess the efficacy of protection in response to any of these modifications to the schedule 
as determined by the Advisory Committee on Immunization Practices (ACIP) and World 
Health Organization (WHO).  Effective levels of protection can be determined by 
comparing neutralizing ability against IgM and IgG for any patients with abnormal 
responses to vaccination to better assess the necessity or lack thereof for subsequent 
boosters for appropriate stimulation of the immune response to rabies antigen.  Paired 
with other immunological techniques such as, cytokine assays, selectively purifying and 
assaying sample fractions (IgM versus IgG), the wealth of rabies immunological data will 
be expanded and contribute to future research and development of alternative 
vaccinations as well as more targeted treatment options.  
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